[Pathogenetic importance of prostacyclin in atherosclerosis].
D015121:6-Ketoprostaglandin F1 alpha / Q000502:physiology; D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology* / Q000503:physiopathology; D001792:Blood Platelets / Q000378:metabolism; D001808:Blood Vessels / Q000503:physiopathology; D004036:Diet, Atherogenic; D011464:Epoprostenol / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood; D008077:Lipoproteins, LDL / Q000502:physiology; D008079:Lipoproteins, VLDL / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D012306:Risk; D013312:Stress, Physiological / Q000150:complications; D013927:Thrombosis / Q000209:etiology / Q000503:physiopathology; D013928:Thromboxane A2 / Q000502:physiology; D013997:Time Factors
D008054:Lipid Peroxides; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol
Patogeneticheskoe znachenie prostatsiklina pri ateroskleroze.